This post was originally published on this site
Shares of Opko rose as much as 24%, before paring gains to trade 9.4% higher at $1.16.
Merck will take over the clinical and regulatory activities related to the vaccine, as well its commercialization once the drugmaker files a joint application with Opko unit ModeX Therapeutics to test it in humans, the company said.
Opko will receive an upfront payment of $50 million and is eligible for milestone payments of up to $872.5 million, plus royalties, on global sales.
There is currently no vaccine for the Epstein-Barr virus, which is the leading cause of mononucleosis, or mono, commonly called the “kissing disease”.
